Nutraceutix issued Australian patent

The Australian Patent Office has issued Nutraceutix, Inc. a patent for BIO-tract.

It is the third international patent, from many patents pending, that the technology has been awarded based on BIO-tract's ability to protect sensitive ingredients like probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract.

Steve Moger, President and CEO of Nutraceutix comments: "Many years ago, we recognized the need for an effective probiotic and nutraceutical delivery technology -- one that draws from proven pharmaceutical principals, but does so in a fashion that is economically feasible in the nutritional supplement marketplace. With BIO-tract, we have addressed this need."

In the case of probiotics, three critical barriers must be overcome to fully benefit the consumer.

  • Survival of these beneficial, but fragile organisms through the manufacturing process
  • Survival on the store shelf
  • Safe passage through the harsh stomach acids that may denature the organisms      

BIO-tract products incorporate proven processes and technologies to overcome these barriers.

How BIO-tract works

Once ingested, BIO-tract tablets form a protective layer, which shields probiotic organisms from the acidic conditions of the stomach. After passing from the stomach to the intestinal tract, the tablets release the organisms at optimal rates determined by formulation.

Broad applications for BIO-tract

Application of the BIO-tract delivery system is not limited to probiotics. It has been applied to many other ingredients that benefit from effective gastric acid protection, buffering, controlled release and once-daily dosing. Custom BIO-tract formulations allow the controlled release of active ingredients at rates ranging from just a few hours to all day long.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Doctors have a poor understanding of long COVID in children, report says